Short answer
Boston Scientific (BSX) filed an 8-K current report with the SEC on October 28, 2026 reporting Item 2.02 (Results of Operations and Financial Condition), Item EX-99.1 (Exhibit EX-99.1). Q3 2026 financial results announced for the quarter ended September 30, 2026.
Boston Scientific 8-K event analysis
AI summary of each reported item and its exhibits
Item 2.02 · Results of Operations and Financial Condition
- Q3 2026 financial results announced for the quarter ended September 30, 2026
- Investors should review Exhibit 99.1 for revenue, earnings, guidance and business-segment performance 乐友
Item EX-99.1 · Exhibit EX-99.1
- Q3 net sales $5.138B, up 1.5%, but GAAP EPS fell to $0.40 from $0.51
- Adjusted EPS $0.73, down from $0.75, with litigation charges $81M and restructuring charges $63M
- Growth concentrated in Cardiovascular, up 1.9%, and Neuromodulation, up 13.0%; Urology declined 3.1%
- Full-year guidance reduced to approximately 4.25% reported sales growth and adjusted EPS $3.16 to $3.18
- Q4 outlook calls for sales decline of 3.0% to 1.0% and adjusted EPS $0.77 to $0.79, reflecting near-term operating pressure
Generated from the filing text and exhibits; verify against the original. What 8-K item codes mean
Other Boston Scientific 8-K filings
Get the next BSX 8-K as it lands
Follow BSX for push alerts, or ask the research agent what this filing means.